Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles

The advent of RNA-encapsulated lipid nanoparticles (LNPs) has sparked a revolutionary transformation in biopharmaceutical innovation. Yet, as the landscape evolves, how will the industry adjust to diversifying applications and scales?

Dive into the discussion with David Sokolowski, Global Workflow Manager at Cytiva, and Jason Coleman, Lead Field Application Scientist at Precision NanoSystems (now part of Cytiva) to learn how manufacturing workflows, processes, and technologies can be leveraged for mRNA vaccine and therapeutic development.

Gain insights into the challenges and opportunities of navigating the diversity and complexity of mRNA-LNPs. Explore strategies to meet the demands of RNA-LNP production across different therapeutic applications and clinical development stages. Learn about essential scale-up, analytics, and facility considerations to streamline GMP manufacturing workflows and uphold product quality.